分类档案: 生命科学

订阅生命科学RSS提要

是的,UCANN!

Patentees 和 inventors of cannabis compounds may be happy to learn a district court in Colorado recently held that, based 上 the record before it, U.S. Patent No. 9,730,911, entitled “Cannabis extracts 和 methods of preparing 和 using same,” is not directed to unpatentable natural phenomena. United Cannabis Corporation v. Pure Hemp Collective Inc., No. … 继续阅读

联邦巡回法院审议膳食补充剂的专利主题事项资格

上周,联邦巡回法院再次权衡专利主题的资格,发现某些含有氨基酸的膳食补充剂和相关使用方法符合专利条件。在Natural Alternatives Int’l v。Creative Compounds,LLC中,联邦巡回法院撤回了加利福尼亚南区地方法院的裁决,该裁决裁定:… 继续阅读

个性化药物专利的令人担忧的趋势

On Nov. 20, 2012, a three-judge panel of the Court of Appeals of the Federal Circuit, in PerkinElmer Inc., 和 NTD Laboratories Inc. v. Intema Ltd. (2011-1577), held that the claims in U.S. Patent 6,573,103 (the ‘103 patent”) are invalid as drawn to noneligible subject matter under 35 U.S.C. § 101.… 继续阅读

审查标准:对专利挑战者的启示

审查标准经常被引用,但在专利案件中却常常被认为是结果决定性的。联邦巡回法院最近的三项裁决表明,针对已在联邦法院进行有效性质疑的已发布专利的审查标准与针对可专利性审查的专利申请所产生的结果差异… 继续阅读

CLS银行: The patent eligibility of computerized trading platforms for exchanging obligations

通过  Barry Wilson and 马丁·巴德(Martin Bader),2012年7月9日,美国联邦巡回法院三名法官组成的小组 CLS Bank International诉Alice Corporation (第2011-1301号上诉)("CLS Bank"),根据35 U.S.C.决定了专利资格的案例§101.在一项分割决定中,小组推翻了地区法院’认定三项Alice Corporation专利要求计算机化… 继续阅读

最高法院确认,仿制药制造商可以在专利诉讼中质疑商标使用代码的描述

Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S 566 U.S. ___, 132 S. Ct. 1670 (Apr. 17, 2012) 通过 Nagendra Setty 和 Bill Blonigan The Hatch-Waxman Act Congress designed the Hatch-Waxman Act (codified at 21 U.S.C. § 355(b), (j), (l) 和 35 U.S.C. §§ 156, 271, 和 282) to inspire medical innovation by giving medical-device … 继续阅读

法院在减轻故意侵犯专利的损害赔偿方面发挥更大作用

Bard Peripheral Vascular,Inc.诉W.L.血块&Associates,Inc.(联邦法院,2012年6月14日),作者:马丁·巴德尔(Martin Bader)和比尔·布洛尼根(Bill Blonigan)。戈尔故意侵犯了巴德’的人造血管移植专利。地方法院随后决定将陪审团人数加倍’的1.856亿美元赔偿金。血块… 继续阅读

第102节:不符合条件的索赔书

通过  Anthony Kuhlmann and 巴里·威尔逊(Barry Wilson)自美国最高法院以来已经三个月了’s decision in Prometheus 和, with the recent grant-vacate-remand of Ultramercial to the Federal Circuit, the patent bar is left to speculate 上 the application of this holding both within 和 outside of medical diagnostics.… 继续阅读

将普罗米修斯应用于无数:可能的结果

通过 巴里·威尔逊 On March 26, 2012, the U.S. Supreme Court issued a much anticipated GVR (grant [certiorari], vacate 和 remand) order in the Association for Molecular Pathology v. the United States Patent Office (a.k.a. ACLU v. Myriad), remanding the case to the Federal Circuit for reevaluation in light of the Supreme Courts’ recent decision … 继续阅读

第八节声明—在橙皮书专利中不要求专利申请的情况下,仍然是通行通用批准的可行途径

通过 Nagendra Setty 和 Mark E. McGrath In its recent decision in AstraZeneca Pharmaceuticals LP v. Apotex Corp., Nos. 2011-1182 –2011-1190(2012年2月9日,美联储)(以下简称“AstraZeneca Decision”) (Rader*, Bryson &林恩(Linn),联邦巡回法院确认了特拉华州的一项决定,根据该决定,由于未提出索赔而驳回了侵权诉讼… 继续阅读

Supreme Court Holds That a 法 of Nature Applied Using Known 和 Obvious Steps Is Not Patent Eligible

通过 Kevin Capps On March 20, 2012, the Supreme Court issued its much-anticipated decision in Mayo Collaborative Services, DBA Mayo Medical Laboratories, et al. v. Prometheus Laboratories, Inc., with potentially far-reaching ramifications for pharmaceutical 和 biotechnology companies, particularly those developing diagnostic methods 和 assays.… 继续阅读
LexBlog

滚动此页面,单击链接或继续浏览我们的网站,即表示您同意我们按照我们的说明使用Cookie。 Cookie 和 Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored 上 your device in the future, you can find out more 和 adjust your preferences 这里 .

同意